Nicolaas Van Renne

Dr. Nicolaas Van Renne

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2017 in Gut
Verified
Journal Article
Open access
PDF file
NRNicolaas Van Renne
Nicolaas Van Renne
ASArmando Andres Roca Suarez
Armando Andres Roca Suarez
FDFrancois H T Duong
Francois H T Duong
CGClaire Gondeau
Claire Gondeau
DCDiego Calabrese
Diego Calabrese
JLJoachim Lupberger
Joachim Lupberger
Background and aims HCV infection is a leading risk factor of hepatocellular carcinoma (HCC). However, even after viral clearance, HCC risk remains elevated. HCV perturbs host cell signalling to maintain infection, and derailed signalling circuitry is a key driver of carcinogenesis. Since protein phosphatases are regulators of signalling events, we aimed to identify phosphatases that respond to HCV infection with relevance for hepatocarcinogenesis. Methods We assessed mRNA and microRNA (miRNA) expression profiles in primary human hepatocytes, liver biopsies and resections of patients with HCC, and analysed microarray and RNA-seq data from paired liver biopsies of patients with HCC. We revealed changes in transcriptional networks through gene set enrichment analysis and correlated phosphatase expression levels to patient survival and tumour recurrence. Results We demonstrate that tumour suppressor protein tyrosine phosphatase receptor delta (PTPRD) is impaired by HCV infection in vivo and in HCC lesions of paired liver biopsies independent from tissue inflammation or fibrosis. In liver tissue adjacent to tumour, high PTPRD levels are associated with a dampened transcriptional activity of STAT3, an increase of patient survival from HCC and reduced tumour recurrence after surgical resection. We identified miR-135a-5p as a mechanistic regulator of hepatic PTPRD expression in patients with HCV. Conclusions We previously demonstrated that STAT3 is required for HCV infection. We conclude that HCV promotes a STAT3 transcriptional programme in the liver of patients by suppressing its regulator PTPRD via upregulation of miR-135a-5p. Our results show the existence of a perturbed PTPRD–STAT3 axis potentially driving malignant progression of HCV-associated liver disease.

8 July 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
ECEmilie Crouchet
Emilie Crouchet
SLShen Li
Shen Li
MSMozhdeh Sojoodi
Mozhdeh Sojoodi
SBSimonetta Bandiera
Simonetta Bandiera
NFNaoto Fujiwara
Naoto Fujiwara
TBThomas Baumert
Thomas Baumert
Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients, for which chemopreventive strategies are lacking. Recently, we developed a simple human cell-based system modeling a clinical prognostic liver signature (PLS) predicting liver disease progression and HCC risk. In a previous study, we applied our cell-based system for drug discovery and identified captopril, an approved angiotensin converting enzyme (ACE) inhibitor, as a candidate compound for HCC chemoprevention. Here, we explored ACE as a therapeutic target for HCC chemoprevention. Captopril reduced liver fibrosis and effectively prevented liver disease progression toward HCC development in a diethylnitrosamine (DEN) rat cirrhosis model and a diet-based rat model for nonalcoholic steatohepatitis–induced (NASH-induced) hepatocarcinogenesis. RNA-Seq analysis of cirrhotic rat liver tissues uncovered that captopril suppressed the expression of pathways mediating fibrogenesis, inflammation, and carcinogenesis, including epidermal growth factor receptor (EGFR) signaling. Mechanistic data in liver disease models uncovered a cross-activation of the EGFR pathway by angiotensin. Corroborating the clinical translatability of the approach, captopril significantly reversed the HCC high-risk status of the PLS in liver tissues of patients with advanced fibrosis. Captopril effectively prevents fibrotic liver disease progression toward HCC development in preclinical models and is a generic and safe candidate drug for HCC chemoprevention.

2 September 2019 in Viruses
Verified
Journal Article
Open access
PDF file
RWRuifang Wei
Ruifang Wei
NRNicolaas Van Renne
Nicolaas Van Renne
HNHans Nauwynck
Hans Nauwynck
Porcine circovirus type 2 (PCV2) is the etiological agent of PCV2-associated diseases (PCVAD). PCV2 targets lymphoblasts, and pigs suffering from PCVAD display lymphocyte depletion in lymphoid tissues. PCV2 infection of lymphoblasts has not been studied. Here, the replication cycle of PCV2 (abortion strain 1121 and PMWS strain Stoon1010) in T-lymphoblasts was examined. The expression of Rep and Cap were found for both viral strains, while progeny virus was detected for Stoon1010 but not for 1121. PCV2 attached to 11–26% (1121-Stoon1010) of the T-lymphoblasts while 2.6–12.7% of cells showed virus internalization. Chondroitin sulfate (CS) was present on 25% of T-lymphoblasts, and colocalized with PCV2 on 31–32% of the PCV2+ cells. Enzymatic removal of CS reduced PCV2 infection. PCV2 infection was decreased by chlorpromazine, cytochalasin D and Clostridium difficile toxin B for both viral strains and by amiloride for 1121 but not for Stoon1010. Inhibiting either endosome acidification or serine proteases strongly reduced PCV2 infection. Three-dimensional analysis of Cap structure demonstrated a better Cap-nucleic acid affinity for Stoon1010 than for 1121. Taken together, PCV2 binds to T-lymphoblasts partially via CS, enters via clathrin-mediated endocytosis, and disassembles under functions of a pH-drop and serine proteases. Strain Stoon1010 displayed an enhanced viral binding, a specific receptor-mediated endocytosis, an increased Cap-nucleic acid affinity, and a more productive infection in T-lymphoblasts than 1121 did, indicating an evolution from 1121 to Stoon1010.

20 November 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
NRNicolaas Van Renne
Nicolaas Van Renne
RWRuifang Wei
Ruifang Wei
NPNathalie Pochet
Nathalie Pochet
HNHans Nauwynck
Hans Nauwynck
Porcine Circovirus Type 2 (PCV2) is a pathogen that has the ability to cause often devastating disease manifestations in pig populations with major economic implications. How PCV2 establishes subclinical persistence and why certain individuals progress to lethal lymphoid depletion remain to be elucidated. Here we present PorSignDB, a gene signature database describing in vivo porcine tissue physiology that we generated from a large compendium of in vivo transcriptional profiles and that we subsequently leveraged for deciphering the distinct physiological states underlying PCV2-affected lymph nodes. This systems genomics approach indicated that subclinical PCV2 infections suppress a myeloid leukocyte mediated immune response. However, in contrast an inflammatory myeloid cell activation is promoted in PCV2 patients with clinical manifestations. Functional genomics further uncovered STAT3 as a druggable PCV2 host factor candidate. Moreover, IL-2 supplementation of primary lymphocytes enabled ex vivo study of PCV2 replication in its target cell, the lymphoblast. Our systematic dissection of the mechanistic basis of PCV2 reveals that subclinical and clinical PCV2 display two diametrically opposed immunotranscriptomic recalibrations that represent distinct physiological states in vivo, which suggests a paradigm shift in this field. Finally, our PorSignDB signature database is publicly available as a community resource ( http://www.vetvirology.ugent.be/PorSignDB/ , included in Gene Sets from Community Contributors http://software.broadinstitute.org/gsea/msigdb/contributed_genesets.jsp ) and provides systems biologists with a valuable tool for catalyzing studies of human and veterinary disease. Finally, a primary porcine lymphoblast cell culture system paves the way for unraveling the impact of host genetics on PCV2 replication.

11 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NRNicolaas Van Renne
Nicolaas Van Renne
TVThomas Vanwolleghem
Thomas Vanwolleghem
The ability to detect microbial reads from sequencing data has significantly advanced microbiome and infectious disease research. Recently, INVADEseq introduced a technique to extract microbial reads from single-cell RNA sequencing (scRNA-seq) data following 16S rRNA amplification. We hypothesized that this approach could be leveraged to detect viruses in eukaryotic cells without such amplification or prior knowledge, provided they produce viral mRNAs containing poly-A tails. To test this, we aimed to detect Hepatitis B Virus (HBV) reads from liver samples of patients with chronic HBV infection, both with and without HBsAg loss. We successfully detected HBV reads in the liver of viraemic patients, predominantly in hepatocytes and, to a lesser extent, in Kupffer cells. Functionally cured HBV patients with HBsAg loss had undetectable HBV mRNA in the liver. This study demonstrates the ability to extract and identify viral reads from scRNA-seq data without prior knowledge and without specific amplification. This approach can be used for screening scRNA-seq data for the presence of viral reads at single-cell resolution, potentially enhancing our understanding of the cellular distribution of viruses and virus-host interactions.

20 December 2025 in JHEP Reports
Verified
Journal Article
Open access
NRNicolaas Van Renne
Nicolaas Van Renne
FBFleur Ballet
Fleur Ballet
SHStijn Van Hees
Stijn Van Hees
Bart CuypersBart Cuypers
Bart Cuypers
ADArno Furquim d’Almeida
Arno Furquim d’Almeida
TVThomas Vanwolleghem
Thomas Vanwolleghem
Chronic viral hepatitis remains a leading cause of liver cancer-related mortality worldwide. We aimed to identify genetic markers associated with hepatocellular carcinoma (HCC) risk in precancerous liver biopsies from patients with chronic HBV or HCV infection. We conducted a multicenter nested case-control study including biopsied patients with chronic viral hepatitis from eight hospitals across Europe and Canada. Cases developed HCC a median of 7.1 years (range 1.5-26.8) after baseline liver biopsy, irrespective of antiviral treatment initiation, and were matched to controls by age, sex, infecting virus, fibrosis stage, and follow-up duration. A semi-supervised machine-learning approach was applied to liver RNA sequencing data, with de novo HCC development as the outcome. Immunohistochemistry and serum analyses were performed on available samples. A 557-gene signature was derived from 106 high-quality liver transcriptome profiles and stratified patients by HCC risk in both the training cohort (p = 3.918 × 10-6) and the validation cohort (p = 0.032). The signature was externally validated for de novo HCC (n = 216; p = 0.048) and for HCC recurrence in patients with cirrhosis irrespective of viral etiology (n = 82; p = 0.026; n = 228; p = 0.030). Single-cell modular score analyses indicated that the HCC risk signature reflects fibrovascular tissue expansion, hepatocyte loss, and increased transcriptional activity of IgA-producing plasma cells. The latter correlated with periportal IgA protein staining in paired transcriptomic-immunohistochemistry analyses. In a small subcohort, serum IgA levels also correlated with liver gene expression, suggesting potential utility as a surrogate marker of liver tissue architecture. A 557-gene liver transcriptomic signature, including IgA plasma cell-related transcripts, identified in pretreatment liver biopsies from patients with chronic HBV or HCV infection, is associated with future HCC risk. Chronic viral hepatitis remains a major global cause of hepatocellular carcinoma (HCC)-related mortality, underscoring the need for improved risk stratification strategies. We identified a 557-gene liver transcriptomic signature, including IgA plasma cell-related transcripts, in pretreatment liver biopsies from patients with chronic hepatitis B and C that is associated with future HCC development. The expression of IgA plasma cell transcripts correlated with periportal IgA protein deposition in liver tissue, supporting their biological relevance. These findings highlight a previously underappreciated association between intrahepatic IgA plasma cells and hepatocarcinogenesis and warrant further investigation into their mechanistic role and potential utility as biomarkers or therapeutic targets for HCC.